NSD2 and acute lymphoblastic leukemia: Thus, Liu’s group designed PROTAC 84 (LLC0424), which degrades NSD2 with nanomolar potency (DC50 = 20 nM, Dmax = 96%) in acute lymphoblastic leukemia (ALL) RPMI-8402 cells.